W. K. Alfred Yung

Dr. Yung is professor of Neuro-Oncology at The University of Texas MD Anderson Cancer Center (MDACC), where he holds the Margaret and Ben Love Chair of Clinical Cancer Care. He was chair of the Department of Neuro-oncology (1999-2015) and co-director (1999-2015) of the MDACC Brain Tumor Center. During his tenure, the department has achieved much, including approval of temozolomide and bevacizumab by the FDA for GBM, development and funding of the National Cancer Institute (NCI)-funded Brain Tumor SPORE, building of the D24 smart oncolytic virus program, leadership in the NCI-funded CNS tumor clinical trial consortia and creation of the GBM Agile, a global adaptive clinical trial platform. Dr. Yung has served as editor-in-chief of Neuro-Oncology (2007-2014), and co-chair of the NCI Brain Malignancy Steering Committee (2011-2017). He was appointed to Vice President Biden’s Cancer Moonshot Blue Ribbon Panel in 2016. He is currently serving as Special Scientific Advisor of National Brain Tumor Society (NBTS), Chair of SAB for Asia Foundation for Cancer Research (AFCR), member of SAC for Ludwig Institute of Cancer Research (LICR), member of SAB for DNATrix, Interleukin CTI, Quadriga, Denovo Biopharma, and a member of the MDACC Moonshot executive committee.